Omjara tablets 150mg, manufactured by GlaxoSmithKline, contains Momelotinib hydrochloride (YJ code: 4291083F2029, standard: 150mg 1 tablet). This JAK1, JAK2, and ACVR1 inhibitor is specifically indicated for the treatment of intermediate or high-risk myelofibrosis with anemia, providing a dual benefit by addressing both disease symptoms and anemia.
Omjara tablets 150mg
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).
